secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001104659-23-121848
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharma receives Nasdaq deficiency notice for delayed Q3 10-Q filing
-------------------------------------------------------------------------

- Nasdaq notified Eagle on Nov 27, 2023 of non-compliance with Rule 5250(c)(1) due to late Q3 10-Q.
- Company has until Jan 26, 2024 to submit a compliance plan; if accepted, Nasdaq may extend to May 7, 2024.
- Failure to regain compliance could lead to delisting; hearing may be requested but no assurance of success.
- No financial impact disclosed; risk of trading suspension or delisting if plan not accepted or filing not made.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465923121848/0001104659-23-121848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465923121848/tm2331615d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-121848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer